Kenvue offers defensive brands, improving volumes and a 29.3% probability-weighted upside case, but the core opportunity remains merger-arbitrage execution.
Overview
Kenvue is the world’s largest pure-play consumer-health company by revenue, spun out of Johnson & Johnson in 2023 and selling trusted OTC and personal-care products in more than 165 countries. Its three segments generated FY2025 net sales of **$15.1 billion**, with approximately 50% outside North America. Tylenol, Neutrogena, Aveeno, Listerine and BAND-AID provide leading positions, professional endorsements and repeat-purchase demand. Q2 2026 showed operational stabilization: sales rose 3.0% to $3,955 million, organic growth was 1.6%, and volume returned to positive territory at 0.7%. However, adjusted gross margin fell to 60.2% and adjusted operating margin to 22.1% as tariffs, inflation, foreign exchange and brand investment offset productivity savings. Adjusted EPS rose 6.9% to $0.31 but missed the $0.32 consensus. At $17.83, valuation is approximately 15.1x forward non-GAAP P/E and 12.0x EV/TTM EBITDA, with a roughly 4.7% dividend yield. The key catalyst is Kimberly-Clark’s pending $48.7 billion acquisition, targeted for the second half of 2026, with $2.1 billion of run-rate EBITDA synergies.